Liquidia (NASDAQ:LQDA) General Counsel Sells $1,053,914.38 in Stock

Liquidia Corporation (NASDAQ:LQDA) General Counsel Russell Schundler sold 14,738 shares of Liquidia stock in a transaction on Monday, July 13th. The shares were sold at an average price of $71.51, for a total transaction of $1,053,914.38. Following the completion of the sale, the general counsel owned 605,962 shares of the company’s stock, valued at $43,332,342.62. This represents a 2.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Down 3.2%

Liquidia stock opened at $75.27 on Friday. The company has a market capitalization of $6.69 billion, a PE ratio of 537.68 and a beta of 0.55. Liquidia Corporation has a 12-month low of $14.04 and a 12-month high of $82.96. The firm’s fifty day moving average is $67.74 and its 200 day moving average is $48.10. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. The firm’s revenue was up 4187.1% compared to the same quarter last year. As a group, sell-side analysts predict that Liquidia Corporation will post 3.02 EPS for the current fiscal year.

Institutional Investors Weigh In On Liquidia

Hedge funds and other institutional investors have recently made changes to their positions in the business. Handelsbanken Fonder AB acquired a new stake in shares of Liquidia in the 2nd quarter worth about $1,993,000. Fulcrum Equity Management acquired a new position in Liquidia during the 2nd quarter valued at about $399,000. Fluent Financial LLC acquired a new position in Liquidia during the 2nd quarter valued at about $287,000. FNY Investment Advisers LLC bought a new stake in Liquidia during the 2nd quarter worth approximately $1,395,000. Finally, Seven Fleet Capital Management LP raised its stake in shares of Liquidia by 124.5% in the first quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock worth $7,732,000 after purchasing an additional 113,609 shares during the last quarter. 64.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $68.00 target price on shares of Liquidia in a research report on Thursday, June 4th. Oppenheimer set a $75.00 price target on Liquidia in a report on Friday, June 5th. HC Wainwright raised their price objective on Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a research note on Friday, June 5th. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Finally, BTIG Research upped their target price on Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Three research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Liquidia currently has a consensus rating of “Moderate Buy” and an average target price of $68.88.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).